{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:01:46Z","timestamp":1785391306574,"version":"3.55.0"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) classification remains the cornerstone of prognostic assessment in metastatic renal cell carcinoma (mRCC). However, whether metastatic burden and host-related inflammatory and nutritional biomarkers meaningfully improve prognostic discrimination beyond IMDC has not been fully established. This study aimed to evaluate whether expanded prognostic models incorporating metastatic burden, bone metastasis, neutrophil-to-lymphocyte ratio (NLR), albumin, and lactate dehydrogenase (LDH) improve survival discrimination beyond IMDC in a real-world mRCC cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively evaluated 104 patients with mRCC treated at a single tertiary oncology center. Overall survival (OS), defined from the diagnosis of metastatic disease, was analyzed using Kaplan\u2013Meier analysis and Cox proportional hazards regression models. Sequential multivariable Cox models were constructed by progressively adding metastatic burden, NLR, albumin, and LDH to the IMDC model. An alternative model incorporating bone metastasis status was also evaluated. Model performance was assessed using Harrell\u2019s concordance index (C-index), \u22122 Log Likelihood statistics, and likelihood-ratio (LR) tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort consisted predominantly of male patients (69.2%), with a median age of 60.3 years at metastatic diagnosis. According to IMDC classification, 24.0% of patients were favorable risk, 51.9% intermediate risk, and 24.0% poor risk. Median OS was 85.36 months in the favorable-risk group, 38.11 months in the intermediate-risk group, and 18.27 months in the poor-risk group (log-rank p&amp;lt;0.001). Elevated NLR was associated with significantly shorter OS in Kaplan\u2013Meier analysis and with increased mortality in univariate Cox analysis (HR\u00a0=\u00a01.86, 95% CI 1.09\u20133.20, p=0.024), while higher serum albumin was associated with improved OS in univariate analysis (HR\u00a0=\u00a00.53, 95% CI 0.30\u20130.91, p=0.021). The fully expanded model demonstrated the highest discrimination (Harrell\u2019s C-index 0.720), compared with 0.664 for the IMDC-only model. However, none of the sequential additions beyond IMDC significantly improved model performance according to likelihood-ratio testing, and metastatic burden, bone metastasis, NLR, albumin, and LDH did not retain independent prognostic significance after multivariable adjustment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this real-world mRCC cohort, IMDC remained the dominant determinant of survival outcomes. Although expanded prognostic models incorporating metastatic burden and host-related biomarkers provided modest numerical improvements in model discrimination, they did not confer statistically significant incremental prognostic value beyond IMDC. These findings support the continued central role of IMDC for prognostic stratification in routine clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1887870","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T05:40:49Z","timestamp":1785390049000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond IMDC: do expanded models improve survival discrimination in metastatic renal cell carcinoma? A real-world cohort study"],"prefix":"10.3389","volume":"16","author":[{"given":"Erdo\u011fan","family":"\u015eeyran","sequence":"first","affiliation":[{"name":"University of Health Sciences (SBI), Van Education and Research Hospital","place":["Van, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azer","family":"G\u00f6kmen","sequence":"additional","affiliation":[{"name":"University of Health Sciences (SBI), Van Education and Research Hospital","place":["Van, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre","family":"Haf\u0131zo\u011flu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Republic of T\u00fcrkiye (TC) Saglik Bakanligi Bursa Sehir Hastanesi","place":["Nil\u00fcfer, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.eururo.2022.03.006","article-title":"European association of urology guidelines on renal cell carcinoma: 2025 update","volume":"87","author":"Bex","year":"2025","journal-title":"Eur Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.05.537","article-title":"ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up of renal cell carcinoma","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"key":"B7","article-title":"NCCN clinical practice guidelines in oncology: kidney cancer. Version 2.2025","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. Version 2.2025","year":"2025"},{"key":"B8","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S1470-2045(14)71222-7","article-title":"The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study","volume":"16","author":"Ko","year":"2015","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2020.07.008","article-title":"Prognostic value of inflammatory biomarkers in metastatic renal cell carcinoma: A systematic review and meta-analysis","volume":"38","author":"Mori","year":"2020","journal-title":"Urol Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: A systematic review and meta-analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"B11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40425-018-0315-0","article-title":"Change in neutrophil-to-lymphocyte ratio and outcomes in metastatic renal cell carcinoma treated with immune checkpoint blockade","volume":"6","author":"Lalani","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s12032-014-0841-7","article-title":"Prognostic significance of serum albumin in patients with metastatic renal cell carcinoma","volume":"31","author":"Stenman","year":"2014","journal-title":"Med Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.40.9631","article-title":"Serum lactate dehydrogenase predicts for overall survival benefit in metastatic renal cell carcinoma","volume":"30","author":"Armstrong","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2017.09.016","article-title":"Comparative genomic profiling of metastatic site-specific renal cell carcinoma reveals potential new therapeutic targets","volume":"4","author":"Becerra","year":"2019","journal-title":"Eur Urol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.21869","article-title":"Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis patterns and their association with survival","volume":"4","author":"Dudani","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.08.012","article-title":"Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy","volume":"65","author":"McKay","year":"2014","journal-title":"Eur Urol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-015-0122-0","article-title":"Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis","volume":"34","author":"Santoni","year":"2015","journal-title":"J Exp Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100634","article-title":"Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program","volume":"7","author":"Rebuzzi","year":"2022","journal-title":"ESMO Open"},{"key":"B19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.15586\/jkcvhl.v12i4.403","article-title":"Meet-URO score validation in real-world patients with metastatic renal cell carcinoma receiving first-line pembrolizumab plus axitinib: A subanalysis of the prospective proPAXI study","volume":"12","author":"Air\u00f2","year":"2025","journal-title":"J Kidney Cancer VHL"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2340\/1651-226X.2025.44533","article-title":"Baseline blood markers and metastatic burden add prognostic value independently of IMDC risk in real-world metastatic renal cell carcinoma patients treated with ipilimumab plus nivolumab","volume":"64","author":"Kheir","year":"2025","journal-title":"Acta Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-024-02593-1","article-title":"Prognostic significance of inflammatory markers in patients with advanced renal cell carcinoma receiving nivolumab plus ipilimumab","volume":"29","author":"Nakayama","year":"2024","journal-title":"Int J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1887870\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T05:40:51Z","timestamp":1785390051000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1887870\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":21,"alternative-id":["10.3389\/fonc.2026.1887870"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1887870","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"article-number":"1887870"}}